Atara Biotherapeutics (ATRA) Stock: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$9.48
1.02 (12.06%)
â˛
5d:
+7.6%
30d:
+0.42%
90d:
-12.87%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATRA is fairly priced but lacks strong directional signals. At -23.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATRA is fairly priced but lacks strong directional signals. At -23.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.22
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$18.15
47.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $9.48, which is considered fair relative to its 30-day fair value range of $8.69 to $9.81. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.1) compared to its historical average (13.5). Remarkably, the market is currently pricing in an annual earnings decline of 23.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a downtrend. Immediate support is located at $7.83, while resistance sits at $9.92. The stock is showing strong short-term momentum, up 12.1% recently.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.67 (+44.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a downtrend. Immediate support is located at $7.83, while resistance sits at $9.92. The stock is showing strong short-term momentum, up 12.1% recently.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.67 (+44.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.69 -
$9.81
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.1%)
- BULLISH: Trading 44.2% below Wall St target ($13.67)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.69 -
$9.81
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.83
Resistance Level
$9.92
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.14
Wall Street Target
$13.67
(+44.2%)
Revenue Growth (YoY)
-96.4%
Profit Margin
-269.4%
Valuation Discount vs History
-23.1% cheaper
PE vs Historical
6.1 vs 13.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.1%
(market-implied from PE analysis)
1-Year Target
$8.53
(-10%)
2-Year Target
$7.68
(-19%)
3-Year Target
$6.91
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6â14)
$15.21
(+60%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.1 to 13.5
Stabilization Target:
$20.86
(+120.0%)
PE Expansion Potential:
+120.0%
Share & Embed Analysis
Last updated: October 03, 2026 6:12 PM ET
Data refreshes hourly during market hours. Next update: 7:12 PM
Data refreshes hourly during market hours. Next update: 7:12 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
